Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial
暂无分享,去创建一个
Xin Huang | J. Desai | G. Demetri | J. Verweij | M. Heinrich | S. George | P. Casali | I. Judson | M. Blackstein | Xin Huang | C. Baum | G. McArthur | J. Morgan | C. Garrett | M. Shah | Jaap Verweij | Jayesh Desai | Ian R Judson | A. Oosterom | George D Demetri | Manisha H Shah | Michael C Heinrich | Grant McArthur | Suzanne George | Christopher R Garrett | Carlo L Bello | Charles M Baum | Paolo G Casali | Martin E Blackstein | Jeffrey A Morgan | Allan T van Oosterom | Christopher D Fletcher | C. Bello | C. Fletcher | M. Shah
[1] C. Antonescu,et al. Sunitinib (SU) response in imatinib-resistant (IM-R) GIST correlates with KIT and PDGFRA mutation status. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[2] J. Blay,et al. Outcome of patients with advanced gastro-intestinal stromal tumours crossing over to a daily imatinib dose of 800 mg after progression on 400 mg. , 2005, European journal of cancer.
[3] Ming-Hui Chen,et al. Hypothyroidism may accompany SU11248 therapy in a subset of patients (pts) with metastatic (met) gastrointestinal stromal tumors (GIST) and is manageable with replacement therapy , 2005 .
[4] J. Blay,et al. Interruption of imatinib (IM) in GIST patients with advanced disease: Updated results of the prospective French Sarcoma Group randomized phase III trial on survival and quality of life , 2005 .
[5] M. von Mehren,et al. Gastrointestinal stromal tumors. , 2005, Hematology/oncology clinics of North America.
[6] C. Antonescu,et al. Acquired Resistance to Imatinib in Gastrointestinal Stromal Tumor Occurs Through Secondary Gene Mutation , 2005, Clinical Cancer Research.
[7] C. Leutner,et al. Acquired resistance to imatinib in gastrointestinal stromal tumours caused by multiple KIT mutations. , 2005, The Lancet. Oncology.
[8] P. Marynen,et al. Mechanisms of resistance to imatinib mesylate in gastrointestinal stromal tumors and activity of the PKC412 inhibitor against imatinib-resistant mutants. , 2005, Gastroenterology.
[9] Rossella Bertulli,et al. Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial , 2004, The Lancet.
[10] Wei Zhang,et al. A Missense Mutation in KIT Kinase Domain 1 Correlates with Imatinib Resistance in Gastrointestinal Stromal Tumors , 2004, Cancer Research.
[11] Angela Greco,et al. A new mutation in the KIT ATP pocket causes acquired resistance to imatinib in a gastrointestinal stromal tumor patient. , 2004, Gastroenterology.
[12] P. Medina,et al. Bevacizumab: An Angiogenesis Inhibitor with Efficacy in Colorectal and Other Malignancies , 2004, The Annals of pharmacotherapy.
[13] K. Hatakeyama,et al. Late resistance to imatinib therapy in a metastatic gastrointestinal stromal tumour is associated with a second KIT mutation , 2004, British Journal of Cancer.
[14] M. van Glabbeke,et al. Use of c-KIT/PDGFRA mutational analysis to predict the clinical response to imatinib in patients with advanced gastrointestinal stromal tumours entered on phase I and II studies of the EORTC Soft Tissue and Bone Sarcoma Group. , 2004, European journal of cancer.
[15] N. Pryer,et al. SU11248 inhibits tumor growth and CSF-1R-dependent osteolysis in an experimental breast cancer bone metastasis model , 2004, Clinical & Experimental Metastasis.
[16] D. Hallahan,et al. The receptor tyrosine kinase inhibitor SU11248 impedes endothelial cell migration, tubule formation, and blood vessel formation in vivo, but has little effect on existing tumor vessels , 2004, Angiogenesis.
[17] A. D. Van den Abbeele,et al. Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[18] Gerald McMahon,et al. SU11248 maintenance therapy prevents tumor regrowth after fractionated irradiation of murine tumor models. , 2003, Cancer research.
[19] U. Vanhoefer,et al. Vascular endothelial growth factor receptor tyrosine kinase inhibitors: PTK787/ZK 222584. , 2003, Seminars in oncology.
[20] N. Pryer,et al. SU11248 inhibits KIT and platelet-derived growth factor receptor beta in preclinical models of human small cell lung cancer. , 2003, Molecular cancer therapeutics.
[21] M. Heinrich,et al. SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo. , 2003, Blood.
[22] Samuel Singer,et al. PDGFRA Activating Mutations in Gastrointestinal Stromal Tumors , 2003, Science.
[23] Juthamas Sukbuntherng,et al. In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.
[24] G. Demetri,et al. Management of malignant gastrointestinal stromal tumours. , 2002, The Lancet. Oncology.
[25] A. D. Van den Abbeele,et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. , 2002, The New England journal of medicine.
[26] G. Demetri,et al. Clinical management of gastrointestinal stromal tumors: before and after STI-571. , 2002, Human pathology.
[27] J. Buckner,et al. Contrast of Response to Dacarbazine, Mitomycin, Doxorubicin, and Cisplatin (DMAP) Plus GM-CSF Between Patients with Advanced Malignant Gastrointestinal Stromal Tumors and Patients with Other Advanced Leiomyosarcomas , 2002, Cancer investigation.
[28] B. Yeap,et al. The effect of surgery and grade on outcome of gastrointestinal stromal tumors. , 2001, Archives of surgery.
[29] E. van den Berg,et al. Soft tissue leiomyosarcomas and malignant gastrointestinal stromal tumors: differences in clinical outcome and expression of multidrug resistance proteins. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[30] M. van Glabbeke,et al. New guidelines to evaluate the response to treatment in solid tumors , 2000, Journal of the National Cancer Institute.
[31] R. DeMatteo,et al. Two hundred gastrointestinal stromal tumors: recurrence patterns and prognostic factors for survival. , 2000, Annals of surgery.
[32] J. Lasota,et al. Gastrointestinal stromal tumors – definition, clinical, histological, immunohistochemical, and molecular genetic features and differential diagnosis , 2000, Virchows Archiv.
[33] S. Hirota,et al. Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. , 1998, Science.
[34] K. K. Lan,et al. Discrete sequential boundaries for clinical trials , 1983 .
[35] R. D. Hunter,et al. WHO Handbook for Reporting Results of Cancer Treatment , 1980 .
[36] K Watson,et al. Flinders Medical Centre. , 1976, The Australasian nurses journal.
[37] R. Melzack. The McGill Pain Questionnaire: Major properties and scoring methods , 1975, PAIN.